Good Morning, ASAM Chapter Presidents and Advocacy Leaders:

SAMHSA has recently posted the following message on its website:

Congress has taken action in the recent Consolidated Appropriations Act, 2023 that impacts federal requirements for Drug Enforcement Administration (DEA) registrants, including those involved in OUD treatment. SAMHSA and DEA are actively working to develop further guidance related to these changes. Please frequently check this webpage for further updates and guidance. Read here: https://www.samhsa.gov/medication-assisted-treatment

ASAM’s webpage has been updated, accordingly, to include a link to this new SAMHSA message here:  https://www.asam.org/advocacy/practice-resources/buprenorphine-management

Thank you for your continued patience as we wait for further federal guidance.

Author: adweb.admin

Nick Covanes is the C.E.O. and Creative Director of Adwebvertising, LLC and has been a leader in the industry since 2011. Nick is experienced in all facets of digital marketing and provides this experience to individual businesses and organizations to help them realize their full growth potential.